{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-21-006115","form_type":"8-K","ticker":"BICX","cik":"0001443863","company_name":"BioCorRx Inc.","filed_at":"2021-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.128616+00:00","generated_at":"2026-06-29T06:05:46.214832+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCorRx awarded $3.5M NIDA grant for first-in-human trial of BICX104 implant","bullets":["Award of ~$3.5M from NIDA for second phase (UH3) of grant; total NIDA funding now ~$5.7M.","Funding supports first-in-human clinical trial of BICX104, an implantable naltrexone pellet for opioid use disorder.","Company previously received FDA clearance to proceed to human trials; aims to begin trial in 2021.","Grant is non-dilutive, covering substantial costs toward FDA approval for BICX104."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-21-006115","json":"https://secwatch.observer/filing/0001477932-21-006115.json","markdown":"https://secwatch.observer/filing/0001477932-21-006115.md","text":"https://secwatch.observer/filing/0001477932-21-006115.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1443863/000147793221006115/0001477932-21-006115-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1443863/000147793221006115/bicx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T06:05:46.214832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}